Here we go yet again

Here we go yet again

This morning Lilly announced they have acquired the rights to an oral GLP-1. Per a post on the FirstWord Pharma web site;

“Eli Lilly entered into an agreement to develop Chugai Pharmaceutical’s oral non-peptidic GLP-1 receptor agonist OWL833 for the treatment of type 2 diabetes, the companies reported Thursday. Under the deal, Eli Lilly will make an upfront payment of $50 million to Chugai, with the latter also eligible for milestones and royalty payments, if the drug is approved.”

At the moment Novo Nordisk is the leading the way in the oral GLP-1 category with the oral version of semaglutide. We say at the moment for in typical Novo fashion they are studying the damn thing to death. We suppose one day they will actually submit the drug to the FDA we just don’t know when that day will be.

While it is likely Novo will get this drug on the market well before the Lilly version comes along the Lilly deal is consistent with the current trend in diabetes drugs. The GLP-1 category continues to expand and an oral version in what right now is an injectable drug category has blockbuster potential. Therefore, Lilly will let Novo do all the heavy lifting in developing the oral side then come along with their version likely offered at a lower price point and round and round we go.

While we’re at EASD next week we’ll also be looking for some insight into just what Sanofi plans to do with Amedlog their biosimilar short-acting insulin. Will they offer it at a deep discount ala what Lilly did with Basaglar or will they do what they typically do in diabetes and screw up a peanut butter and jelly sandwich.

Speaking of our wine drinking friends we hope to gain some additional insight into their entry into the insulin pump market via their relationship with Google. So far all we know is it will be a patch pump and they like everyone else who wants to enter this market will be targeting insulin using Type 2 patients. Also, like all the newbies their device is way cool, but the real question is can they make it in and more importantly achieve any scale.

We’re sure that at EASD we’ll see our fair share of interconnected devices, smart insulin pens and apps. More than likely they’ll also be lots of CGM wannabes too. What we likely will not see is any toy that has a real plan for success in the market. Yep these toys will be way cool and whiz bang but other than that we doubt any wannabe will have a clue as to how get their toy played with.

Honestly, we don’t like going to any conference with such a pessimistic attitude, but this pessimism comes with the gray hairs on our head. It also helps when we actually do see something that is more than way cool whiz bang. It’s been a long time since that has happened, but we can always hope.

As Momma Kliff used to say; “Better to go expecting nothing and be pleasantly surprised then it is to go expecting big things and be disappointed.”